The disclosure provides biodegradable amphiphilic liquid crystalline copolymers that can readily self-assemble to nanoparticles in aqueous solutions and also allow for encapsulation of hydrophobic pharmaceutically active molecules.

The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.

Disclosed are crosslinked particles (e.g., microparticles) that are capable of storing and releasing drugs. The particles can be macroparticles, microparticles, or nanoparticles and can be composed of polyester backbones. The particles can be loaded with a drug. The particles can degrade in vivo to release the drug. The particles can be prepared by crosslinking functionalized polyester backbones and loaded with a given drug. The particles of the present disclosure can be injected with a syringe. In some embodiments, the particles of the present disclosure are administered in connection with a surgery and release the drug after the site of the surgery for a period of 1-6 months.

A method for forming encapsulated gold nanoparticles mixes mangiferin into a liquid medium to form a reducing agent solution. Gold salts are mixed into the reducing agent solution. Reaction of the gold salts is permitted, in the absence of any other reducing agent, to form a nanoparticle solution of stabilized, biocompatible gold nanoparticles coated with mangiferin. The gold salts can consist of AuCl4, or can consist of radioactive gold salts. A cancer therapy method injects a solution of mangiferin encapsulated gold nanoparticles directly into a solid tumor. A solution consisting of an aqueous or alcoholic medium and mangiferin encapsulated gold nanoparticles is provided. The mangiferin encapsulated gold nanoparticles can have core sizes of ˜5-20 nm and total sizes of ˜20-120 nm.

The present invention relates to a method for constructing a nanodrug with adhesion in small intestine, including activating a basic amino acid with a small molecular catalyst, adding a polysaccharide solution and reacting to obtain an amphiphilic polymer; then adding a drug solution and mixing uniformly, to obtain drug-loaded nanoparticles including a hydrophilic portion that is the basic amino acid and a hydrophobic portion that is the polysaccharide and drug, wherein the drug has radioprotective effect or can inhibit ionizing radiation-induced cell death; and adding the drug-loaded nanoparticles to a dopamine solution to obtain a nanodrug including the basic amino acid and polydopamine on the surface after the reaction. The present invention provides an oral nanodrug with adhesion in intestinal tract, and the nanodrug has good biocompatibility, adhesion in small intestine and mucus barrier penetration ability, and can withstand the acid and alkali environment in the gastrointestinal tract.

A targeted drug delivery system to be used in treating osteomyelitis is provided. Gelatin nanoparticles suitable for a drug release in treating the osteomyelitis includes magnetite and antibiotics, wherein the antibiotics are gentamicin. A production method of the gelatin nanoparticles includes the steps of: dissolving collagen, enabling a precipitation of gelatin having a large mass of molecule, removing the gelatin having a small sized molecule mass, re-dissolving the gelatin with the large mass of the molecule in water and adjusting a pH of the gelatin to 10-13 with a NaOH solution after the dissolving is completed, adding 2-6 mg/ml magnetite dispersion, adding acetone dropwise, adding 0.02-0.2 ml 5-9 mg/ml genipin as a cross linker, and adding 3.5-7 mg/ml 0.1-1 ml antibiotics on magnetic gelatin nanoparticles.

The present developments provide methods and compositions for treating and/or preventing autoimmune diseases. In certain aspects, the present disclosure relates to the use of short peptides loaded inside of nanoparticle nanospheres, nanocapsules, or PEGylated nanoparticles. Additionally, peptide-metal nanoparticle drug conjugates are described and disclosed. In some embodiments, these nanoparticles, whether polymer based or metal-conjugated, when linked or coupled to bioactive peptides provided herein, may be capable of interacting with CD40 proteins or CD40 complexes, and thereby may interfere with the ability of CD40 to interact with CD154. The present disclosure also relates to the use of such nanoparticle-peptide conjugates in reducing the inflammatory response, and in particular, the autoimmune inflammatory response. The present disclosure also relates to the use of such short peptides to prevent or reverse autoimmune disease, in particular in type 1 diabetes and multiple sclerosis, in individuals suffering from such diseases.

The present invention relates to a drug delivery system, comprising: a drug-loaded carbon nanotube formed by a carbon nanotube and a drug molecule adsorbed on the surface of the carbon nanotube, a modifying material capable of enhancing water solubility and biocompatibility of the drug delivery system, and a targeting molecule. The present invention further relates to preparation and use of the drug delivery system. The present invention provides a new strategy for selectively targeting and effectively eliminating cancer stem cells, which is conducive to fundamentally preventing recurrence and metastasis of a cancer induced by cancer stem cells.

Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm.sup.3 and about 0.15 g/cm.sup.3, and/or a specific surface area (SSA) of at least 18 m.sup.2/g, 20 m.sup.2/g, 25 m.sup.2/g, 30 m.sup.2/g, 32 m.sup.2/g, 34 m.sup.2/g, or 35 m.sup.2/g. Methods for making and using such compositions are also provided.

A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug and a poorly aqueous soluble polymer, and a resuspending material selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate, carboxymethyl ethylcellulose, and pharmaceutically acceptable salt forms thereof.